GLP-1 News: Ozempic, Wegovy, Mounjaro & Zepbound

New FDA-approved treatments for psoriasis, atopic dermatitis, and hidradenitis suppurativa in 2026 may affect GLP-1 users managing overlapping conditions.

A new peer-reviewed study explores amylin analogues as a promising next-generation obesity treatment. Here's what GLP-1 users need to know.

A peer-reviewed case report in JAAD Case Reports describes a rare drug-related skin rash associated with tirzepatide, the active ingredient in Mounjaro and Zepbound.

A new peer-reviewed study explores how GLP-1 and related peptides may protect the brain against neurodegeneration. Here's what it means for patients.

Novo Nordisk is retiring the Rybelsus name in the US, rebranding the oral semaglutide tablet as the 'Ozempic pill.' Here's what patients need to know.

A new JAMA study finds genetic variants may influence how well semaglutide and tirzepatide work — and what side effects you experience. Here's what to know.

A new lab study tested an ionic liquid-based pill to deliver semaglutide orally. Here's what the early research means for GLP-1 patients.

A new peer-reviewed study finds GLP-1 drugs like Ozempic may have ocular effects during rapid metabolic changes, raising questions about eye monitoring.

A new case series of 30 patients published in Scandinavian Journal of Gastroenterology finds semaglutide may help treat intractable chronic diarrhea.

The FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, potentially ending compounded versions of Ozempic and Mounjaro.

Eli Lilly's oral GLP-1 Foundayo has launched for obesity, but early data suggests it may be trailing Novo Nordisk's Wegovy pill. Here's what patients should know.

A peer-reviewed study in Neurology examines a possible link between GLP-1 drugs like Ozempic and a rare eye condition called NAION. Here's what patients should know.

A new meta-analysis in Neurology examines whether GLP-1 drugs like semaglutide raise the risk of NAION, a rare form of vision loss. Here's what patients should know.

A new peer-reviewed study indirectly compares tirzepatide and oral semaglutide for weight loss. Here's what the findings mean for patients considering GLP-1 options.

A new peer-reviewed letter in Diabetology & Metabolic Syndrome spotlights the gut-brain axis in obesity and type 1 diabetes — here's what it means for GLP-1 users.

A randomized clinical trial in JAMA Psychiatry finds semaglutide may improve motivated behavior in people with major depressive disorder. Here's what to know.

A new National Psoriasis Foundation review published in JAMA Dermatology explores how GLP-1 drugs like Ozempic may benefit people living with psoriasis.

A new peer-reviewed study in CJASN compares SGLT2 inhibitors and GLP-1 receptor agonists for kidney protection in type 2 diabetes. Here's what it means for patients.

A new peer-reviewed study warns that GLP-1 drug side effects are being confused with surgical complications — with real medicolegal consequences for doctors.

A new peer-reviewed review marks 25 years of insulin glargine. Here's what people on Ozempic, Wegovy, or Zepbound should understand about basal insulin.

Boehringer Ingelheim's survodutide matched Wegovy-like weight loss in Phase 3 trials and may help preserve muscle mass. Here's what patients should know.

A new peer-reviewed study suggests stevia plant extracts may upregulate GLP-1 in beta cells. Here's what it means for Ozempic and Wegovy users.

The FDA has approved a higher dose of injectable semaglutide. Here's what current Ozempic and Wegovy users need to know about this development.

A new peer-reviewed paper in Endocrine Reviews explores how GLP-1 medications may help patients recovering from long COVID and post-viral syndromes.

A new peer-reviewed systematic review examines which dietary strategies work best alongside GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.

A new JAMA Internal Medicine study examines weight regain after stopping tirzepatide. Here's what GLP-1 users need to know about discontinuing treatment.

A new peer-reviewed study in J Mol Neurosci finds semaglutide may protect nerves from chemotherapy-induced damage by restoring key cellular pathways.

A new peer-reviewed study finds GLP-1 drugs like Ozempic may cause rash and hair loss — but could also help treat inflammatory skin conditions.

A new peer-reviewed review in Cardiovascular Diabetology examines a decade of heart safety trials for GLP-1 drugs. Here's what the findings mean for patients.

A new peer-reviewed study finds GLP-1 levels may be associated with acute kidney injury risk following cardiac surgery. Here's what patients should know.

Four major medical organizations issued a correction to their joint GLP-1 nutrition advisory. Here's what it means for people on Ozempic or Wegovy.

A Phase 3 trial in India compared generic semaglutide to brand-name Ozempic in type 2 diabetes patients. Here's what the SIZE-DM study found.

Lilly shares fell after Foundayo's early launch struggled compared to oral Wegovy. Here's what it means for patients seeking oral GLP-1 options.

A new JAMA study shows oral semaglutide sustains long-term reductions in cardiovascular disease risk factors. Here's what it means for patients.

A new real-world study of 2,549 patients compares side effects, treatment persistence, and weight loss between tirzepatide and semaglutide. Here's what it found.

A new peer-reviewed study compares SGLT2 inhibitors, non-steroidal MRAs, and GLP-1 medications for protecting kidneys in non-diabetic patients.

A new peer-reviewed study compares oral semaglutide 25mg pills to Wegovy injections for obesity and type 2 diabetes. Here's what the findings mean for patients.

Novo Nordisk reports positive trial results for oral semaglutide in adolescents with type 2 diabetes, potentially expanding its use beyond adults.

A new peer-reviewed study finds social media drug ads are fueling more patient requests for GLP-1 weight loss medications like Ozempic and Wegovy.

A new peer-reviewed study in Europace found semaglutide may reduce atrial remodeling after heart attack, potentially lowering AFib risk in heart failure patients.

A pilot study from the SLIM LIVER trial found semaglutide may slow epigenetic aging in people with HIV and metabolic liver disease. Here's what the findings mean.

A new peer-reviewed study in J Med Econ used SURMOUNT-5 trial data to compare the cost-effectiveness of Zepbound vs Wegovy for obesity treatment in the US.

A new peer-reviewed study examines how GLP-1 drugs like Ozempic affect wound healing after free flap breast reconstruction surgery. Here's what patients need to know.

A pilot study from the SLIM LIVER trial found semaglutide may affect epigenetic aging markers in people with HIV and fatty liver disease. Here's what to know.

A new peer-reviewed study in BJGP Open reveals how German primary care doctors experience prescribing GLP-1 medications like semaglutide in real-world practice.

A new peer-reviewed study in Acta Paediatr finds GLP-1 drugs like liraglutide and semaglutide meaningfully change body composition in teens with obesity.

A new real-world study compares tirzepatide (Mounjaro/Zepbound) to GLP-1 drugs on protecting heart and kidney health in people with metabolic syndrome.

A new meta-analysis finds GLP-1 drugs like Ozempic may reduce serious limb complications in peripheral artery disease patients. Here's what it means for you.

A new peer-reviewed study finds semaglutide pretreatment may improve reproductive outcomes in women with overweight or obesity who are struggling with infertility.

A new case report in Hormones Research in Paediatrics suggests GLP-1 drugs like Ozempic may benefit teens with rare mitochondrial diabetes (MELAS).

A new peer-reviewed review in Annals of Medicine examines how GLP-1 drugs like semaglutide may protect against strokes in people with type 2 diabetes.

A large Scandinavian study found GLP-1 receptor agonists like Ozempic may be linked to a lower risk of developing Parkinson's disease. Here's what we know.

A phase 3a trial published in Lancet Diabetes & Endocrinology found cagrilintide plus semaglutide outperformed semaglutide alone for weight loss in Japan and Taiwan.

A new peer-reviewed case study in the Journal of Bone and Mineral Research raises important questions about GLP-1 drugs like semaglutide and bone density loss.

A new peer-reviewed review in Advances in Therapeutics explores how GLP-1 drugs like Ozempic could benefit people with cystic fibrosis and related diabetes.

A new peer-reviewed study explores how tirzepatide, the drug in Mounjaro and Zepbound, may lower blood pressure and support cardiac function in a rat model.

A new peer-reviewed review finds liraglutide, semaglutide, and tirzepatide may slow or reverse prediabetes progression — here's what it means for patients.

A new peer-reviewed rat study finds repeated semaglutide treatment reduced cocaine-seeking behavior, raising hope for future addiction treatment research.

A new real-world registry study examines how semaglutide and SGLT2 inhibitors affect outcomes in type 2 diabetes patients after acute coronary syndrome.

A new peer-reviewed rodent study in EBioMedicine finds tirzepatide, the drug in Mounjaro and Zepbound, may reduce motivation for cocaine. Here's what we know.

A new BMC Public Health study reveals significant knowledge gaps among GLP-1 drug users. Here's what people taking Ozempic or Wegovy should understand.

A new BMJ study explains why regaining weight after stopping GLP-1 medications like Ozempic is driven by biology, not willpower or personal failure.

A new Diabetes Care study explores how tirzepatide's dual GIP and GLP-1 action may explain why Mounjaro and Zepbound outperform semaglutide-based drugs.

New peer-reviewed research explores how semaglutide targets liver disease directly, following its approval as the first GLP-1 treatment for MASH with fibrosis.

A new peer-reviewed review in Current Diabetes Reports finds GLP-1 drugs deliver meaningful weight loss and glycemic benefits for people with type 2 diabetes.

A new peer-reviewed network meta-analysis compares tirzepatide (Zepbound/Mounjaro) head-to-head with sleeve gastrectomy for weight loss. Here's what it found.

A new peer-reviewed UAE study reveals real-world GLP-1 prescribing patterns and early weight and blood pressure outcomes. Here's what patients should know.

A real-world study in Advances in Therapeutics finds tirzepatide outperforms other obesity medications on quality of life and work outcomes in U.S. adults.

New research links the absorption enhancer in oral semaglutide (Rybelsus) to gut microbiome disruption and inflammation. Here's what patients should know.

A new real-world study in Transplantation journal examines how kidney transplant recipients tolerate and respond to tirzepatide (Mounjaro/Zepbound).

A new case report in ACG Case Reports Journal finds semaglutide helped a woman with ulcerative colitis achieve remission. Here's what patients should know.

A new peer-reviewed study compares US cost-effectiveness thresholds to Most Favored Nations under a 2025 executive order — here's what it means for GLP-1 pricing.

A new JACC study compares the real-world cardiovascular effectiveness of GLP-1 drugs like Ozempic against SGLT2 inhibitors in people with type 2 diabetes.

A new peer-reviewed review in Frontiers in Pharmacology details how olanzapine disrupts metabolism across multiple organs — relevant for GLP-1 users.

A new peer-reviewed study in EClinicalMedicine finds GLP-1 receptor agonists may reduce erectile dysfunction risk in men with type 2 diabetes.

A new peer-reviewed study published in medRxiv examines whether GLP-1 receptor agonists like Ozempic could help patients with Wolfram syndrome, a rare genetic disease.

New research links abnormal GLP-2 secretion to fatty liver disease progression — but GLP-1 drugs like Ozempic and Wegovy appear unaffected. Here's what to know.

A new peer-reviewed paper in the New England Journal of Medicine breaks down how GLP-1 drugs like Ozempic and Mounjaro work — and what it means for patients.

A new peer-reviewed paper in Psychiatry Research explores how semaglutide and tirzepatide may affect mood, anxiety, and addictive behaviors in patients.

A large Italian study of 378,914 type 2 diabetes patients finds kidney disease patterns have changed over 15 years — here's what GLP-1 users need to know.

A new meta-analysis in Clinical Kidney Journal finds GLP-1 drugs like Ozempic may be safe for kidney transplant recipients managing metabolic complications.

A new peer-reviewed study compares US drug cost-effectiveness thresholds to Most Favored Nations under a 2025 executive order — here's what it means for GLP-1 prices.

A new peer-reviewed analysis of SURMOUNT-1 and SURMOUNT-4 trials finds tirzepatide shifts BMI categories and improves cardiometabolic risk factors in people with obesity.

A new peer-reviewed study finds tirzepatide (Mounjaro/Zepbound) can move patients down a full BMI category, a meaningful shift in obesity classification.